Business Wire

MODULEX-GRUPPEN

22.5.2024 18:36:27 CEST | Business Wire | Pressemeddelelse

Del
MODULEX GRUPPEN OFFENTLIGGØR NY CFOO

Modulex Gruppen er glade for at kunne annoncere udnævnelsen af Mikkel Arreborg som Chief Finance og Operations Officer med base i koncernens hovedkvarter i Billund. Mikkel har en baggrund som CFO med en dokumenteret track record for strategisk finansielt lederskab og operationel ekspertise på tværs af forskellige brancher.

I løbet af sin tid som CFO hos Auto Solutions Group demonstrerede Mikkel enestående færdigheder i at styre finansielle operationer på tværs af et konglomerat af virksomheder. Hans ansvarsområder omfattede tilsyn med budgettering, finansiel rapportering og aktiv deltagelse i bestyrelsesmøder. Han stod især i spidsen for en omfattende omstrukturering af økonomiafdelingen og implementerede nye systemer og processer for at øge effektiviteten. Mikkel spillede en afgørende rolle i det succesfulde opkøb af Etac Bil i Norge, hvor han viste sin instrumentelle rolle i opkøb og integrationer.

"Det er mig en stor ære at blive en del af Modulex-teamet", siger Mikkel Arreborg. "Jeg er meget begejstret for at deltage i den spændende rejse, der ligger forude for koncernen, og den enestående mulighed for at lære af og bidrage til alle Modulex enheder på tværs af forskellige lande og kulturer."

Før han kom til Modulex Gruppen, havde Mikkel betydelige roller hos bl.a. PwC og BDO. Han har en kandidatgrad i revision og en diplomuddannelse i erhvervsøkonomi med speciale i regnskab og økonomistyring.

Ketil M. Staalesen, CEO i Modulex Gruppen, er begejstret for udnævnelsen af Mikkel og udtaler: "Jeg er virkelig begejstret for, at Mikkel har besluttet sig for at blive en del af vores team. Det er en meget vigtig rolle i fremtiden for den globale koncern, og det er en rolle, jeg arbejder meget tæt sammen med. Jeg var imponeret over Mikkels strategiske sans, hans umiddelbare observation af, hvordan han kunne gøre en forskel, og hans begejstring for at lære og lære alle forretningsenhederne at kende globalt."

Mikkel er en indflydelsesrig leder, der er forpligtet til at fremme et samarbejdsmiljø og bidrage til Modulex' formålsdrevne virksomhedskultur.

For mere information om Modulex, besøg vores hjemmeside https://modulex.com/ eller kontakt vores medierelationsteam på media@modulex.com

Om Modulex Gruppen:

Modulex blev grundlagt i 1963 af LEGO Koncernen og har siden 2009 været ejet af ledende partnere og eksterne investorer og er globalt førende inden for visuel kommunikation. Med rødder i dansk design excellence og et modulært skiltningskoncept har Modulex udviklet sin platform med design, wayfinding, skræddersyede løsninger og brandimplementeringer. I 2019 lancerede Modulex fabrikken i Billund, som er både ISO 9001 og 14001 certificeret, en bæredygtig produktlinje og blev tildelt Green Network-diplomet for 10. gang i træk. Den multinationale koncern har flere produktionsfaciliteter globalt. Koncernen er repræsenteret i over 300 byer i 45 lande.

For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240522566437/da/

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye